glp-1 and creatine CreatineForHealth receptor agonists (like semaglutide tirzepatide) are revolutionizing obesity and type 2 diabetes care, but up to 40% of weight loss may come from lean mass. Could help? Ribeiro The Synergistic Benefits of Combining

Regardless, as they increase in popularity, they will likely change the GLP-1 industry

The next major M&A opportunity may involve companies with differentiated oral GLP-1 assets, GLP-1/GIP dual agonists, amylin combinations, long-acting dosing platforms, or MASH-relevant metabolic therapies

Body mass index, abdominal fatness and the risk of gallbladder disease

Investigations into the impact of antidiabetic medications on PD risk have yielded mixed outcomes

This phenomenon is orchestrated by the enteroendocrine hormones GLP-1 and Gastric Inhibitory Peptide (GIP), both of which concomitantly facilitate insulin secretion (Figure 1)